🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

    Sanofi-aventis Healthcare Pty Ltd

    Immune Thrombocytopenia Purpura

    phase 1 other active

    1 trial

  2. A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy participants aged 18 to 55 years

    Sanofi-aventis Healthcare Pty Ltd

    Immuun system diseases

    phase 1 other active

    1 trial

  3. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline

    Tuberculosis

    phase 1 other active

    1 trial

  4. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  5. A trial to evaluate the absolute bioavailability of cenerimod in healthy male participants

    Viatris Pharmaceuticals Co.,

    Not applicable - healthy volunteer trial

    phase 1 other active

    1 trial

  6. AB-SA01 (10^8 PFU per phage)

    Armata Pharmaceuticals

    Healthy Volunteers

    phase 1 mab completed

    1 trial

  7. ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

    Actinium Pharmaceuticals

    Leukemia

    phase 1 mab completed

    1 trial

  8. ACU193

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  9. AK120 or placebo- Part 1- Cohort 1

    Akeso

    Atopic Dermatitis

    phase 1 small molecule completed

    1 trial

  10. ALPN-101

    CNS Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. ALS-002158

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule terminated

    1 trial

  12. ALS-002200

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule completed

    1 trial

  13. AMX0114

    Amylyx Pharmaceuticals EMEA B.V.

    ALS

    phase 1 small molecule active

    1 trial

  14. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  15. APOC-III-L-Rx

    IONIS PHARMACEUTICALS INC

    Elevated Triglycerides (TG)

    phase 1 small molecule completed

    1 trial

  16. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Healthy

    phase 1 small molecule completed

    2 trials

  17. ARC-521 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  18. ARO-AAT Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  19. ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Dyslipidemias

    phase 1 small molecule completed

    1 trial

  20. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 1 small molecule completed

    1 trial

  21. ARO-ATXN2 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Spinocerebellar Ataxia Type 2

    phase 1 small molecule active

    1 trial

  22. ARO-CFB

    Arrowhead Pharmaceuticals Ireland Limited

    IgA Nephropathy

    phase 1 small molecule completed

    1 trial

  23. ARO-HIF2

    Arrowhead Pharmaceuticals Ireland Limited

    Clear Cell Renal Cell Carcinoma

    phase 1 small molecule completed

    1 trial

  24. ARO-RAGE Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources